Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).
Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC). Eng says the combination came about through medical professional's use of bevacizumab in the frontline as a treatment for mCRC, leading one Italian research group to start the TRIBE trial.
The trial studied bevacizumab plus FOLFOXIRI and found the combination improved both progression-free survival (PFS) and response rates over FOLFIRI (irinotecan, fluorouracil, and folinate) alone. The combination also found that patients receiving the combination had a 5-year overall survival (OS) of 25%, as opposed to the standard 13% in mCRC patients. Eng says the one downside to the combination is that patients become more prone to myelosuppression.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More